drugset / Trial / NCT00138164
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
50 enrolled
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Biological therapies, such as denileukin diftitox, may be able to carry cancer-killing substances directly to non-Hodgkin's lymphoma cells. PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Timeline
- Start
- 2004-12
- Primary completion
- 2006-02
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denileukin diftitox | Protein / enzyme biologic | — | Intravenous |